Study wrapper · #418
Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study.
Editor's note
This is a large nationwide retrospective cohort (208,155 post-bariatric-surgery patients, 39,750 on incretin therapy) examining semaglutide and tirzepatide as add-on treatment after metabolic and bariatric surgery. Among those on therapy at least a year, tirzepatide was associated with greater additional weight loss than semaglutide (17.2% vs 12.0% total weight loss; adjusted difference ~5.2 points) in a dose-dependent way, and later post-surgical initiation was associated with more weight loss than earlier. Notably, in matched landmark analyses, pooled incretin therapy was not associated with a reduction in major adverse cardiovascular events (HR 0.91, CI 0.80–1.05) — a null result the authors present honestly. Standard observational caveats apply: confounding by indication, adherence, and the fact that patients starting later may differ systematically. The authors explicitly call for prospective work to establish causality and cardiovascular benefit. Solid comparative signal on weight, appropriately cautious on hard outcomes.
Plain-language abstract
Many people regain weight after weight-loss (bariatric) surgery, so doctors increasingly add medicines like semaglutide or tirzepatide afterward. This large US study used health records from over 208,000 people who had such surgery, nearly 40,000 of whom later took one of these medicines, to see how much extra weight they lost and whether they had fewer serious heart events. Among those who stayed on treatment for at least a year, tirzepatide was linked to more added weight loss than semaglutide (about 17% versus 12% of body weight), and higher doses worked more. Starting the medicine later after surgery was linked to more weight loss than starting soon after. However, when researchers looked at serious heart problems, the medicines were not clearly linked to a lower risk. Because this study used existing records rather than randomly assigning treatment, it cannot prove cause and effect, and the authors say larger prospective studies are needed, especially to confirm any heart benefit.